logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus

< Back

Rexmyelocel-T for critical limb ischaemia in patients with diabetes mellitus

Drugs

Skin Disease, Burns and Wound Care

October 2017


 
The treatment, rexmyelocel-T, is being developed to relieve leg pain at rest and heal leg ulcers. The treatment uses cells from bone marrow which are injected into the damaged blood vessel, where they restore existing blood vessels and create new blood vessels. By improving the blood flow in the limb, this treatment aims to improve the patient’s condition so that they do not require amputation.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts